<DOC>
	<DOCNO>NCT01973062</DOCNO>
	<brief_summary>This phase II trial study well yttrium Y 90 ibritumomab tiuxetan rituximab work treat patient recurrent refractory primary central nervous system non-Hodgkin lymphoma . Radiolabeled monoclonal antibody , yttrium 90 ibritumomab tiuxetan , find cancer cell carry cancer-killing substance without harm normal cell . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving yttrium Y 90 ibritumomab tiuxetan rituximab may kill cancer cell .</brief_summary>
	<brief_title>Yttrium Y 90 Ibritumomab Tiuxetan Rituximab Primary Central Nervous System Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine radiographic response proportion patient refractory recurrent primary central nervous system lymphoma ( PCNSL ) ibritumomab tiuxetan ( yttrium Y 90 ibritumomab tiuxetan ) give intravenous infusion . SECONDARY OBJECTIVES : I . Determine progression free survival patient treat ibritumomab tiuxetan give intravenous infusion . II . Determine overall survival patient treat ibritumomab tiuxetan give intravenous infusion . III . Establish toxicity profile ibritumomab tiuxetan patient population . IV . Use positron emission tomography ( PET ) /magnetic resonance imaging ( MRI ) map distribution Y-90 ibritumomab tiuxetan , calculate Gy deliver base activity find within tumor . OUTLINE : Patients receive rituximab intravenously ( IV ) day 1 . Within 7 9 day , patient receive rituximab IV yttrium Y 90 ibritumomab tiuxetan IV absence disease progression unacceptable toxicity . Distribution dose absorb dose assessed day 11 . Quality life assess screening , day 1 , 36 , 92 , follow-up visit . After completion study treatment , patient follow every 3-6 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients histological diagnosis recurrent refractory primary central nervous system ( CNS ) lymphoma least 1 measurable gadolinium enhance lesion brain MRI scan Karnofsky performance status ( KPS ) &gt; = 60 Patients could 3 prior therapy regimens treatment PCNSL Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L Platelets &gt; = 100 x 10^9/L Hemoglobin ( Hgb ) &gt; 10 g/dL Serum total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) = &lt; 3.0 x ULN Aspartate aminotransferase ( AST ) = &lt; 3.0 x ULN Serum creatinine = &lt; 1.5 x ULN Minimum interval since completion radiation treatment 12 week Minimum interval since last drug therapy : 3 week since completion noncytotoxic agent 4 week since completion nonnitrosoureacontaining regimen 6 week since completion nitrosoureacontaining regimen Patients must sign approve informed consent authorization permit release personal health information Patients corticosteroids stable dos ( less 6 mg daily dexamethasone ) 1 week baseline image Patients potential pregnancy impregnate partner must agree follow acceptable birth control method avoid conception Patients must concurrent malignancy except curatively treat basal squamous cell carcinoma skin carcinoma situ cervix breast , adequately treated stage I II cancer patient complete remission ; patient prior malignancy must diseasefree &gt; = three year Pregnant breastfeeding woman Patients unwilling unable comply protocol Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g . active infection , uncontrolled diabetes , symptomatic congestive heart failure , unstable angina , cardiac arrhythmia , psychiatric illness , etc . ) could cause unacceptable safety risk compromise compliance protocol Known diagnosis human immunodeficiency virus ( HIV ) infection ; prior radioimmunotherapy , prior myeloablative therapy autologous bone marrow transplantation peripheral stem cell rescue , prior external beam radiation therapy 25 % active bone marrow Patients receive filgrastim ( GCSF ) sargramostim ( GMCSF ) within 2 week treatment major surgery within prior 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>